TCL1 mRNA is hyperexpressed in multiple B-cell lymphomas. (A,C) Total RNA was extracted from normal human tissues, normal human peripheral blood B and T cells, and from primary human lymphoma cells; reverse transcribed into cDNA; and then quantitative PCR was performed for TCL1 and β-actin. (A) Expression of TCL1 mRNA relative to β-actin is shown in normal human tissues. (C) Expression of TCL1 mRNA in primary human lymphoma cells is shown relative to TCL1 expression in normal human peripheral blood B cells. Horizontal lines represent the median value for each group. P value on the top of graph represents comparison between normal donor B cells and all lymphomas. P values below the graph represent comparison between normal donor B cells and each lymphoma subtype. All P values were calculated by 2-tailed Student t test. (B,D) Expression of TCL1 mRNA in normal human tissues (B) and different human lymphoma subtypes (D) was determined from publicly available cDNA microarray datasets from the Oncomine database. The number of samples for each tissue type is shown in brackets. CLL indicates chronic lymphocytic leukemia; MCL, mantle cell lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; SMZL, splenic marginal zone B-cell lymphoma; HL, Hodgkin lymphoma; BL, Burkitt lymphoma; MM, multiple myeloma; and HCL, hairy cell leukemia.